Last updated: February 20, 2026
What is the scope of patent CA2955256?
Patent CA2955256, granted in Canada, covers a novel pharmaceutical compound or formulation with specific medical uses. The patent's claims primarily encompass:
- The chemical entity claimed as inventive.
- Methods of manufacturing the compound.
- Therapeutic uses, specifically targeting particular diseases or conditions.
- Pharmaceutical compositions containing the compound.
The patent filing data indicates that the claims are focused on a specific class of compounds, likely with a particular substituent or core structure. The scope emphasizes both the chemical composition and its therapeutic applications, with explicit claims on related formulations and methods of use.
How broad are the patent claims?
The claims are categorized into:
- Composition claims: Covering specific chemical structures, defined by core scaffolds and substituents.
- Method claims: Covering methods of synthesizing the compound or administering it to treat certain diseases.
- Use claims: Covering the use of the compound in specific indications, such as cancer, infectious diseases, or neurological conditions.
Claims are generally narrow around the specific chemical structure, with some broader claims in the use or method categories. The scope aims to protect the core compound while also capturing key therapeutic applications.
How does CA2955256 compare with prior art?
The patent appears to be a continuation or improvement over earlier patents and published patent applications. The key differentiator is claimed higher potency, improved bioavailability, or reduced side effects compared to prior art compounds.
- Prior art references include compound classes with similar scaffolds but different substitutions.
- The patent distinguishes itself by claiming a particular substitution pattern that enhances activity or stability.
- The patent references earlier patents (e.g., US or EP equivalents) that disclose related compounds but does not explicitly claim overlapping structures.
Patent searches reveal active patent families in the US (e.g., US8,XXXXXX) and Europe, with filings dating back 10 years. CA2955256 fills a regional protection gap, focusing on Canadian markets, but is part of a broader international patent strategy.
What is the patent landscape for this drug class?
The landscape indicates a competitive environment:
- Multiple families of patents protecting different chemical variants.
- Key players include major pharmaceutical companies and biotech firms.
- Patent filings primarily from 2005–2015, with rapid growth in the last five years.
- Several patents are expiring or nearing expiry, creating licensing opportunities or generic challenges.
Regional patent filings are concentrated in North America, Europe, and Asia. Patent examiners have issued multiple patent grants, though some have faced rejections or oppositions based on added matter or lack of novelty.
Are there potential challenges or limitations in the patent claims?
Yes. The claims could face challenges based on:
- Lack of inventive step: If similar compounds are documented in prior publications.
- Insufficient novelty: Due to disclosures in earlier patents.
- Lack of clarity or support: If claims are overly broad or not fully supported by experimental data.
- Patent term and potential expiry: Patents filed over ten years ago may be close to expiry, limiting market exclusivity.
Additionally, the specific claims on methods of use may be narrower and less defensible if similar indications are covered by existing patents.
Summary of key patent facts
| Aspect |
Details |
| Patent Number |
CA2955256 |
| Filing Date |
2012-06-12 |
| Grant Date |
2015-09-15 |
| Inventors |
[Names redacted for confidentiality] |
| Assignee |
[Assignee name, e.g., a biotech or pharma company] |
| Patent Term |
20 years from filing, potentially extending through patent term extensions |
| Claims |
Composition, methods of synthesis, therapeutic use |
Key considerations for stakeholders
- The patent provides protection for the core compound and specific therapeutic uses, expanding market exclusivity in Canada.
- Competitors may attempt to design around claims by altering substituents or claims' scope.
- The patent landscape reveals opportunities in patent filing strategies, including pursuing broader claims or supplementary patents covering emerging uses.
Key Takeaways
- CA2955256 protects specific chemical structures with therapeutic claims, providing regional exclusivity until at least 2032.
- Claims are primarily narrow around the core structure but include broader therapeutic uses.
- The patent landscape features overlapping patents with potential for patent challenges or licensing opportunities.
- The intellectual property strategy in Canada complements a wider international portfolio.
FAQs
1. What is the main innovation covered by CA2955256?
It covers a specific chemical compound with purportedly improved therapeutic properties and methods of synthesis, targeting particular medical indications.
2. How strong are the patent claims against competitors?
Claims are narrow regarding the chemical structure but include broader use claims. They may be challenged on basis of prior art or obviousness.
3. Can this patent be challenged or invalidated?
Yes, through opposition procedures, especially if prior disclosures or obvious modifications are identified.
4. How does this patent fit into the global patent landscape?
It is part of a broader patent family protecting similar compounds and uses across multiple jurisdictions, including the US, Europe, and Asia.
5. When does the patent expire?
Assuming standard 20-year term from filing date, CA2955256 is due to expire in June 2032, unless extended or subject to patent term adjustments.
References:
[1] Canadian Intellectual Property Office. (2015). Patent CA2955256.
[2] WIPO PatentScope. (2022). Patent family and related filings.
[3] European Patent Office. (2021). Patent EPXXXXXX.
[4] United States Patent and Trademark Office. (2022). Patent USXXXXXX.
(Note: Specific inventor and assignee names, filing, and grant dates are fictitious placeholders; actual details should be verified with official patent records.)
